Evidence map›Paper›PMID 29761309›Full record

ReviewJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2019

Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Paco E Bravo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. 2-[Scientific reports · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2019: Positron emission tomography, computed tomography and magnetic resonance.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020
    Review
  12. Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Paco E BravoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. paco.bravo@uphs.upenn.edu.
Hospital of the University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary microvascular dysfunction and, its functional consequence, myocardial ischemia are common pathologic features in patients with hypertrophic cardiomyopathy (HCM). Both have been commonly invoked as potential triggers of and/or contributors to the underlying pathophysiological processes leading to heart failure, and malignant ventricular arrhythmias. Positron emission tomography (PET) with myocardial blood flow quantification provides a unique opportunity to evaluate the integrity and function of the coronary microcirculation in HCM. The purpose of the present review is to summarize all the pertinent literature and future perspectives of the role of PET in the evaluation and risk stratification of patients with HCM.

Indexed as

Positron-Emission TomographyCardiomyopathy, HypertrophicChest PainCoronary Artery DiseaseCoronary CirculationHeartHeart FailureHumansMicrocirculationMyocardial IschemiaRisk AssessmentTomography, Emission-Computed, Single-PhotonBasic scienceDiseases/processesModalitiesTests

Identifiers

PMID29761309
OpenAlexW2802170152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.